ClinicalTrials.gg
TerminatedNCT04924192Updated Apr 13, 2026

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

A Phase 2 interventional study of TQB3616 capsules and Anlotinib Hydrochloride capsules in Advanced Lung Carcinoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.

02

Conditions studied

  • Advanced Lung Carcinoma
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with proven small cell lung cancer(SCLC) or/and locally advanced ( Stage ⅢB/ ⅢC), or recurrent (Stage IV) non small cell lung cancer(NSCLC).
  2. Cohort 1: Subjects with SCLC who had previously received at least one chemotherapy containing platinum or got disease progression during chemoradiotherapy or after the last treatment.
  3. Cohort 2: Subjects with locally advanced, metastatic/ NSCLC who had previously received only one PD (L) 1 inhibitor alone or in combination with platinum-based chemotherapy.
  4. Subjects with as defined by 1.1.
  5. Aged ≥ 18 years ; (ECOG) score: 0 \~ 1; Expected survival ≥ 3 months.
  6. Laboratory indicators meet the requirements.
  7. Non-pregnant or non-breastfeeding women; Negative pregnancy subjects.
  8. Subjects voluntarily joined the study and signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who received prior therapy with anlotinib hydrochloride capsules.
  2. Cohort 2: Subjects with epidermal growth factor receptor(EGFR) mutation and anaplastic lymphoma kinase(ALK) translocation.
  3. Subjects with central squamous cell carcinoma with a risk of hemoptysis.
  4. Subjects who have developed or is currently suffering from other within 5 years, with the exception of cured skin basal cell carcinoma and cervical carcinoma in situ.
  5. Subjects who have with symptoms or control of symptoms for less than 2 months.
  6. Subjects with difficulty taking oral medication.
  7. Subjects with uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage.
  8. Subjects with spinal cord compression who have failed to be cured or relieved by surgery and or radiotherapy.
  9. Subjects who have received chemotherapy, radiotherapy or other experimental anticancer therapy within 4 weeks prior to the first dose of the drug.
  10. Subjects who have not recovered to ≤ Grade 1 (excluding alopecia) due to the adverse event of prior therapy.
  11. Subjects with significant surgery or significant traumatic injury within 28 days before randomization.
  12. Subjects with arterial/venous thrombosis within 6 months.
  13. Subjects with a history of psychotropic substance abuse who cannot be withdrawn or have mental disorders.
  14. Subjects with any severe and/or uncontrolled disease.
  15. Subjects whose large vessels are involved by tumor from imaging (CT or MRI).
  16. Subjects who have hemoptysis and maximum daily hemoptysis ≥ 2.5ml within 1 month before the first dose.
  17. Subjects with other factors that might cause the study to be terminated halfway per the judgement of the investigator.

    -

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    TQB3616 capsules+Anlotinib hydrochloride capsules

    TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 21 consective days as a treatment cycle;Anlotinib hydrochloride capsules 12mg, once a day for 2 consecutive weeks and stop for 1 week.

    Drug: TQB3616 capsules · Drug: Anlotinib Hydrochloride capsules

  • Experimental
    TQB3616 capsules +Irinotecan Hydrochloride for Injection

    TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 28 consecutive days as a treatment cycle. Irinotecan Hydrochloride Injection 100 mg/m2 intravenous infusion on D1、D8 and D15, a total of 4-6 cycles.

    Drug: TQB3616 capsules · Drug: Irinotecan Hydrochloride for Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    Percentage of participants achieving complete response (CR) and partial response (PR).

    Time frame: up to 96 weeks

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: up to 96 weeks

  2. Disease control rate(DCR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 96 weeks

  3. Duration of Response (DOR)

    The time when the participants first achieved CR or PR to disease progression or death from any cause.

    Time frame: up to 120 weeks

  4. 6-month progression-free survival rate

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: up to 96 weeks

  5. 6-month and 12-month overall survival rate

    OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: up to 96 weeks

07

Study locations

7 sites
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing Municipality 400000, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
  • Guizhou Provincial People's Hospital
    Guiyang, Guizhou 550002, China
  • The Second Affiliated Hospital of PLA Air Force Military Medical University
    Xi’an, Shanxi 710038, China
  • West China Hospital of Sichuan University
    Chengdou, Sichuan 610041, China
  • Sichuan Cancer Hospital
    Chengdu, Sichuan, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650011, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Sep 2022, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2021
First posted
Jun 11, 2021
StartActual
Aug 18, 2021
Primary completionActual
Sep 27, 2022
CompletionActual
Oct 10, 2022
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04924192
Responsible party
Sponsor
First posted
Jun 11, 2021
Start date
Aug 18, 2021
Primary completion
Sep 27, 2022
Completion
Oct 10, 2022
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Catequentinib hydrochloride

Start the discussion